atai Life Sciences appoints two new independent directors; Camm departs board

ATAI Life Sciences N.V.

Scott Braunstein, M.D. and Laurent Fischer, M.D. appointed as independent supervisory directors, subject to Dutch registration.
Jason Camm stepped down after four years; resignation not due to any disagreement with the company.
New directors bring pharma executive experience as atai advances to later-stage clinical trials.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason Camm

supervisory director

ATAI Life Sciences N.V.

Effective: 2024-05-19
Filed: May 23, 2024, 7:59 PM ET

On May 19, 2024, Jason Camm resigned from his position as supervisory director of ATAI Life Sciences N.V. (the “Company” or “atai”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Camm resigned as supervisory director at ATAI Life Sciences N.V..

Action: resigned
Role: supervisory director

Exact text from the filing

On May 19, 2024, Jason Camm resigned from his position as supervisory director of ATAI Life Sciences N.V. (the “Company” or “atai”).

View on SEC.gov

Source: SEC EDGAR

accession 0001140361-24-027226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.